Intestinal sweet sensing pathways and metabolic changes after
Introduction
Intense investigation of contributory factors has implicated several mechanisms, including 66 alterations in incretin levels, the gut microbiome, bile acids, and an area of interest to our 67 lab: intestinal nutrient sensing. The surgical isolation of duodenum and proximal jejunum 68 appear to be critical in mediating resolution of T2D, supported by outcomes following 69 endoluminal sleeve device insertion and surgical procedures (e.g. RYGB, Biliopancreatic 70 diversion) which exclude a similar region of the intestine from the digestive process (9, 19, 71 20, 21). Further highlighting the importance of proximal bowel isolation are studies in RYGB 72 models showing that the re-introduction of mixed nutrients into the excluded bowel 73 reverses the beneficial effects of surgery on glucose tolerance (7, 8, 22) . Despite recognition 74 of the importance of the proximal small bowel in glucose regulation, a more detailed 75 understanding of the underlying mechanisms remains elusive. RYGB removes a significant 76 part of the proximal small bowel from the physiologic enteral tract in the formation of the 77 biliopancreatic (BP) limb, and prevents nutrient contact with this region of the bowel. We 78 have hypothesized that prevention of nutrient stimulation of mucosal sensors and luminal 79 nutrient transporters in this bowel segment mediates improvements in glucose 80 homeostasis. We previously confirmed the presence of sweet taste receptors (T1R2/3) along 81 this region of bowel, and demonstrated that specific activation of the T1R2/3 receptor by 82 selective agonists resulted in acute up-regulation of the critical intestinal glucose transporter6 physiologically healthy Sprague Dawley (SD) rats leads to a decrease in SGLT1-mediated 85 glucose uptake in the Roux limb (also known as the alimentary limb), which could contribute 86 to the metabolic benefits of the surgery (24) . 87
The aim of this study was to extend our previous work by assessing the role of the sweet 88 taste receptor T1R2/3 in the down-regulation of intestinal SGLT1-mediated glucose uptake 89 after RYGB in the SD rat and to investigate changes in the intestinal nutrient sensing 90 pathway following RYGB in the obese Zucker diabetic fatty (ZDF) rat. We hypothesized that 91 decreased SGLT1-mediated intestinal glucose absorption in the Roux limb after RYGB is due 92 to exclusion of the sweet taste receptor complex in the isolated BP limb. To test this, we 93 developed a model in which isolated BP mucosa can be re-exposed to sweet taste receptor 94 stimulating agonists via an indwelling catheter. Thus, contrary to most previous studies 95 involving infusion of mixed meals, we re-stimulated the BP limb with a specific stimulus that 96 has no caloric value to help isolate the contributions of a specific pathway in the anti-97 diabetic effect of RYGB. 98 8 animals had free access to tap water, and a liquid diet was provided ad libitum from day 2 post-123 operatively (CVS Liquid Nutrition 8oz: 250kcal, 40g carbohydrate, 9g protein, 6g fat). After 5 days 124 animals were returned to pre-operative solid diet (standard chow or Purina 5008). Catheters were 125 inspected and flushed daily to ensure the site of exteriorization was clean, and to maintain patency. 126
Experiment Protocol. Body weights (commencing on the day of surgery) and food intake (pre-operatively 127 and once solid diet was resumed post-operatively) of animals were documented on a daily basis. Blood 128 glucose levels were measured before commencing RYGB surgery and immediately prior to harvest. On 129 the 11 th post-operative day (by which time point the animals' weights have stabilized with no ongoing 130 weight loss and they have been re-established on their regular pre-operative diet) rats were randomized 131 into treatment and control groups. Treatment animals received a 9ml infusion of 0.3% saccharin via the 132 BP catheter, over a 3 hour period commencing at 8am (SD n=6, ZDF n=10). Control animals received 9ml 133 of 0.9% normal saline following the same infusion regime (SD n=3, ZDF n=5). Infusions were delivered 134 via an electronically programmed pump. At harvest, delivery of infusate into the BP limb was confirmed 135 by ensuring the tip of the indwelling catheter was correctly positioned in the duodenum. 136
A further control group of SD rats underwent RYGB with catheter placement but received no infusion at 137 harvest to exclude the effects of mechanical distension in the BP limb (n=4). At the end of the 3 hour 138 infusion period (11am), animals were harvested and tissues collected for analysis. 139
Tissue harvest. Under inhalation anesthesia using isoflurane 2-3% in oxygen, a midline laparotomy was 140 performed and the Roux limb flushed with ice-cold phosphate-buffered saline before harvesting the 141 first 5cm for everted sleeve studies. This segment was divided into equal thirds, which were everted 142 and mounted onto a glass rod for functional glucose uptake assays. The remainder of the Roux limb as 143 well as the common and BP limbs were harvested for mucosal scrapings, with samples being ZDF rats. ZDF body weights were lowest at POD 9, and remained at this level until harvest on POD 11 177 (mean body weight 390.4 ± 11.4g at baseline vs. 337.6 ± 8.2g at harvest; 13.1 ± 1.8% decrease in 178 baseline body weight) ( Figure 1 ). There was no difference in weight loss between the 2 infusion arms 179 (p=0.9). Food intake was decreased in the post-operative period (34.5 ± 0.9 pre-op vs. 22.2 ± 2.3 post-op 180 g/rat/24hr Purina 5008, p<0.01). This decrease remained significant when corrected for body weight 181 Topographic variation of Sglt3b was apparent in both SD and ZDF rats, but was more pronounced in the 206 ZDF rats with 7-to 10-fold higher levels of Sglt3b in the common limb than in the Roux and BP limbs 207 (p≤0.01 for both infusion groups) (Figure 4a ). Levels of Sglt3b were approximately 3-to 5-fold higher in 208 the common limb of bypassed SD rats compared to Roux and BP limb levels (p<0.05 for all SD groups 209 combined) (Figure 4b ). There was no difference in SGLT3b expression between infusion groups of the SDrats. However, in ZDF rats there was a 2.4-fold down-regulation on infusion of saccharin vs. normal 211 saline (p<0.05). 212 213 which improvements in glycemic control are achieved are not well understood. Numerous studies have 217 examined feeding patterns, weight and hormonal changes after RYGB in either obese or diabetic rodent 218 models (4, 13, 25), but few have analyzed changes in the obese and diabetic rat or attempted to 219 delineate the mechanisms mediating change. To this end, we elected to study changes in healthy SD as 220 well as obese ZDF rats. The obese ZDF rat carries an autosomal recessive mutation in the leptin receptor 221 gene leading to hyperphagia, obesity and progressive insulin resistance, closely paralleling the metabolic 222 syndrome in humans. 223
We had previously shown that RYGB leads to down regulation of intestinal glucose absorption capacity, 224 through changes in SGLT1 function (24). We hypothesized that this post-RYGB reduction in intestinal 225 SGLT1-mediated glucose uptake is due to exclusion of the sweet taste receptor T1R2/3 otherwise 226 positioned to detect the presence of glucose in the anatomically normal bowel. We confirmed the 227 presence of the sensor in both models, and observed no changes in mRNA expression of the T1R2 228 component or of the glucose transporter genes SGLT1 and GLUT2 in response to a sweet taste receptor 229 agonist infused into the surgically isolated bowel in either rat strain. However we did find changes in 230 the putative glucose sensor SGLT3b. 231
Studies have shown that the T1R2/3 complex is necessary for SGLT1 up-regulation in response to an 232 increased carbohydrate load (18), and that non-nutritive sweeteners acting at the sweet taste receptor 233 as an alternative to glucose can reproduce this up-regulation as well as elicit an incretin hormone 234 response (15). In our study of the post-RYGB model however, the sweet taste receptor stimulant 235 saccharin did not alter Roux limb glucose uptake when infused into the isolated BP limb. The lack of 236 response to saccharin infusion could be due to one of several reasons. Firstly, the T1R2/3-SGLT1vagal nerve branches or division of enteric nerve plexus within the bowel wall. These factors may also 239 explain why others have found no effect of sweet taste receptor agonists on intestinal glucose 240 absorption in isolated segments of bowel that had been ligated proximally and distally (5). Alternatively, 241 T1R2/3 may exert a more local effect on SGLT1 (autocrine/ paracrine) but not one that reaches as far 242 distally as the jejunum of the Roux limb. Given reports of diminished desire for sweet tasting food post-243 RYGB and descriptions of altered perception of sweet foods on the palate, it is even plausible that either 244 sensitivity or ability of intestinal T1R2/3 to perceive sweet substrates as it did pre-operatively is altered 245 post-RYGB (3, 27). To pre-empt reduced sensitivity post-RYGB we infused a dose of saccharin that is 10 246 times greater than that in saccharin-sweetened sodas. 247
Another possibility for our negative result is that the relevant sweet sensing pathway is one that is 248 independent of the T1R2/3 complex and one for which saccharin is not an agonist. This possibility made 249 us explore SGLT3, another putative glucose sensor. SGLT3 is a neuronally located member of the solute 250 carrier family of proteins that appears to function as a sensor rather than a transporter of glucose (6, 251 10). Binding of glucose (but not saccharin) to SGLT3 leads to membrane depolarization. Thus if SGLT3 is 252 an important nutrient sensor after bariatric surgery, our infusion of saccharine to the BP limb would not 253 reverse the anti-glucose absorptive effects of surgery, consistent with what we have seen. We found 254 higher levels of the putative glucose sensor SGLT3 in the common limb of bowel vs. the BP and Roux 255 limbs in both SD and ZDF rats. The decrease in SGLT3 mRNA level in the Roux limb of RYGB ZDF rats after 256 saccharin infusion are interesting findings and should prompt further investigation of its role in glucose 257 sensing, the pathophysiology of metabolic disease and resolution of T2D after RYGB, including 258 measurement of both its known isomeric forms in rodents (SGLT3a and b). Other groups have also 259 studied changes in glucose transporters and sensors after RYGB in other rodent models. In a study to 260 assess taste preference after RYGB, Bueter et al. found decreased T1R2 levels in the BP limb of bypassedincrease in GLUT2 mRNA levels in both the Roux and common limbs, with decreased SGLT1 in the Roux 263 limb (26). These studies differ from ours in several ways however including the fact that they compared 264 RYGB rats to sham animals rather than expression levels of transporters in RYGB limbs after BP limb 265 infusion with different agents. homeostasis parameters in human subjects post-RYGB following mixed meals administered orally or into 279 the isolated gut (11), most studies suggest that re-stimulation of the proximal bowel with glucose or 280 mixed meal leads to deterioration of glucose tolerance. Our studies take these observations further, 281 attempting to identify the mechanisms involved in these observations by testing specific nutrient 282 sensing pathways. 283 conducted catheter infusion studies in rats early (POD 11) in order to investigate changes in the sweet 285 taste sensing pathway in this early post-operative period. We chose to selectively interrogate one 286 pathway at a time, using saccharin which is specific for T1R2/3 activation rather than challenging the 287 isolated limb of bowel with a mixed meal which may activate multiple pathways and introduce 288
confounding. We have previously demonstrated an acute response (within 3 hours) of intestinal glucose 289 uptake to saccharin stimulation of T1R2/3 and designed the current study based on these data and did 290 not pursue models of longer infusions or repeated infusions over a longer period. 291
The possibility of a type 2 statistical error should be considered due to use of ZDF rats with less 292 predictable disease phenotype expression. To account for this however we used an n=10 in the ZDF 293 saccharin-infused group and n=5 in the ZDF saline-infused group. We would expect this to provide 294 adequate power to detect any meaningful and significant differences. 295
Transcription and post-translational modifications mean that mRNA results cannot be extrapolated/ 296 interpreted to make assumptions about protein levels. However, technical difficulties with antibodies 297 against SGLT1 and T1R2 precluded protein assays in this study. We believe that measurement of 298 functional SGLT1-mediated glucose uptake is an acceptable and likely better surrogate for SGLT1 protein 299 levels as it measures the final step in the process and the extent of functional protein. 300
Changes in intestinal glucose sensing in the pathophysiology of obesity and T2D, and following RYGB 301 require further research to enhance understanding of the gut as an endocrine organ, the effects of 302 RYGB, and its scope as a metabolic as well as bariatric procedure. Analysis of changes in intestinal 303 sensors and transporters at the protein level, and challenging the isolated gut after RYGB with different 304 agonists in a selective manner will add valuable insight into the mechanisms effecting improvements in 305 T2D after surgery. 
